Skip to main
ORIC

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals (ORIC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ORIC Pharmaceuticals Inc is advancing its clinical-stage pipeline, specifically highlighting ORIC-944 and enozertinib, with raised probabilities of approval and promising early clinical data suggesting high efficacy and reduced toxicity. The company reports an encouraging overall response rate (ORR) of 80% in initial patients treated with enozertinib, which is positioned as a potentially best-in-class agent due to its high brain-penetrance and lower off-target toxicities. Furthermore, the ongoing development of its therapies aligns with a significant market opportunity estimated between $3.0 to $3.5 billion annually in the US, indicating a robust financial outlook as the company approaches further program updates and potential Phase 3 trials.

Bears say

ORIC Pharmaceuticals Inc experienced a net loss per share of $(0.33) in the third quarter of 2025, aligning with prior financial projections and indicating continuing financial challenges. The company faces substantial risks, including the potential failure of its lead drug candidates, ORIC-114 and ORIC-944, in clinical trials, which could lead to delays and regulatory hurdles impacting their market introduction. Additionally, the prospect of slower market adoption and diminished peak sales estimates poses further concerns regarding future revenue generation and the financial viability of the company.

Oric Pharmaceuticals (ORIC) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oric Pharmaceuticals (ORIC) Forecast

Analysts have given Oric Pharmaceuticals (ORIC) a Buy based on their latest research and market trends.

According to 10 analysts, Oric Pharmaceuticals (ORIC) has a Buy consensus rating as of Jan 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oric Pharmaceuticals (ORIC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.